Evommune (EVMN) Stock Price, Quote, News & History | Benzinga

SPY767.35+0.54%QQQ718.14+1.17%BTC/USD—DIA—GLD—TLT80.08+0.04%

Evommune Inc (EVMN) Stock Price, Quote, News & History

EVMNNYSE

Trade with Public

Trade with Public

$5.17

-0.76-12.82%

Last update: Oct 16, 7:56 PM

$5.20

-0.73-12.31%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$5.17

Volume / Avg.

1.00 / 684.44K

Day Range

- - -

52 Wk Range

5.64 - 33.20

Market Cap

$188.72M

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

16

Short Interest

11.8%

Days to Cover

3.86

Recent Evommune, Inc. News

Evommune Halts Atopic Dermatitis Program Following Trial Failure

Evommune halts EVO756 development in atopic dermatitis following a Phase 2b trial failure, shifting focus to its EVO301 candidate.

Vandana Singh

Why Mission Produce Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

Mission Produce rose 5.5% after beating Q3 earnings and sales estimates; several stocks rallied, while ServiceTitan and Evommune fell premarket.

Avi Kapoor

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts

Avi Kapoor

Top 3 Health Care Stocks That May Rocket Higher In July

Oversold health care stocks: EVMN, NNNN, NAUT. RSI <30 shows they may be undervalued. EVMN dropped 46% due to trial failure. NNNN & NAUT had 17% & 12% drops.

Avi Kapoor

This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

Wall Street analysts changed outlook on top names, including Alphine Income Property Trust, AAR Corp, and Evommune. See analyst ratings for these stocks.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-74.15M

Investing Cash Flow (TTM)

-200.87M

Financing Cash Flow (TTM)

274.22M

Free Cash Flow (TTM)

-74.65M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-808.00K

Analyst Trends and Forecast

2

May

1

2

Jun

2

1

Aug

2

1

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$5.05M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

18.76

PB Ratio (TTM)

0.68

Earnings Yield % (TTM)

-228.72%

Earnings Yield % (FWD)

-51.64%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$7.65

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$410.00K

Total Cash

$60.03M

Debt to Equity

0.03

Issuance of Debt (TTM)

-$410.00K

Repayment of Debt (TTM)

-$410.00K